{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:18:12Z","timestamp":1790680692937,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejphar.2021.174700","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T02:32:37Z","timestamp":1644028357000},"page":"174700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Targeted treprostinil delivery inhibits pulmonary arterial remodeling"],"prefix":"10.1016","volume":"923","author":[{"given":"Aijun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174700_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618766490","article-title":"Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience","volume":"12","author":"Coons","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.ejphar.2021.174700_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2119\/molmed.2013.00165","article-title":"Molecular mechanisms of pulmonary arterial remodeling","volume":"20","author":"Crosswhite","year":"2014","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejphar.2021.174700_bib3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jps.10021","article-title":"A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling","volume":"91","author":"Desai","year":"2002","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejphar.2021.174700_bib4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/fca-2020-0021","article-title":"Treprostinil in the treatment of pulmonary arterial hypertension","volume":"16","author":"Feldman","year":"2020","journal-title":"Future Cardiol."},{"key":"10.1016\/j.ejphar.2021.174700_bib5","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2353\/ajpath.2010.090832","article-title":"Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells","volume":"176","author":"Fijalkowska","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2021.174700_bib6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/2045-8932.83455","article-title":"Lung transplantation for pulmonary hypertension","volume":"1","author":"George","year":"2011","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ejphar.2021.174700_bib7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2021.174700_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1465-9921-7-9","article-title":"Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells","volume":"7","author":"Growcott","year":"2006","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejphar.2021.174700_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/thoraxjnl-2015-207170","article-title":"The molecular targets of approved treatments for pulmonary arterial hypertension","volume":"71","author":"Humbert","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.ejphar.2021.174700_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/pcad.2002.130041","article-title":"Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension","volume":"45","author":"Jeffery","year":"2002","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.ejphar.2021.174700_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174700_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.phrs.2015.09.010","article-title":"Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP","volume":"102","author":"Lambers","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2021.174700_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205195","article-title":"Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells","volume":"13","author":"Lambers","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2021.174700_bib14","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/HYPERTENSIONAHA.118.11932","article-title":"Targeted delivery of Sildenafil for inhibiting pulmonary vascular remodeling","volume":"73","author":"Li","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2021.174700_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0008-6363(97)00039-4","article-title":"von Willebrand factor: a marker of endothelial dysfunction in vascular disorders","volume":"34","author":"Lip","year":"1997","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2021.174700_bib16","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41467-019-11500-6","article-title":"CD146-HIF-1\u03b1 hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension","volume":"10","author":"Luo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2021.174700_bib17","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174700_bib18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.RES.0000145360.16770.9f","article-title":"Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis","volume":"95","author":"McMurtry","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2021.174700_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/hc0202.101974","article-title":"Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174700_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-391860-4.00017-3","article-title":"Nanoparticle-mediated treatment of pulmonary arterial hypertension","volume":"508","author":"Mosgoeller","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejphar.2021.174700_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0169-409X(99)00040-X","article-title":"Anticancer therapy using glucuronate modified long-circulating liposomes","volume":"40","author":"Oku","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2021.174700_bib22","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1021\/acs.molpharmaceut.7b01003","article-title":"Fasudil and DETA NONOate, loaded in a peptide-modified liposomal carrier, Slow PAH progression upon pulmonary delivery","volume":"15","author":"Rashid","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejphar.2021.174700_bib23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.RES.0000126050.41296.8E","article-title":"Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3\/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension","volume":"94","author":"Schermuly","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2021.174700_bib24","doi-asserted-by":"crossref","first-page":"H1322","DOI":"10.1152\/ajpheart.00136.2018","article-title":"Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension","volume":"315","author":"Thenappan","year":"2018","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2021.174700_bib25","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.00072709","article-title":"Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation","volume":"35","author":"Thenappan","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2021.174700_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fbioe.2017.00079","article-title":"Nanoparticles-emerging potential for managing Leukemia and Lymphoma","volume":"5","author":"Vinhas","year":"2017","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejphar.2021.174700_bib27","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1096\/fj.201802620R","article-title":"Platelet-derived growth factor up-regulates Ca(2+)-sensing receptors in idiopathic pulmonary arterial hypertension","volume":"33","author":"Yamamura","year":"2019","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejphar.2021.174700_bib28","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.113.004136","article-title":"Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments","volume":"128","author":"Zhao","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174700_bib29","article-title":"Metabolomic heterogeneity of pulmonary arterial hypertension","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921008566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921008566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:01:47Z","timestamp":1757977307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921008566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":29,"alternative-id":["S0014299921008566"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174700","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted treprostinil delivery inhibits pulmonary arterial remodeling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"174700"}}